Atmospheric low-temperature argon plasma for the treatment of pruritus: A randomized two-sided placebo-controlled study


* Department of Dermatology, University Hospital Regensburg, Germany † Department of Dermatology, Hospital Munich-Schwabing, Germany 
® Center for Clinical Studies, University Hospital Regensburg, Germany 
© Max-Planck-Institute for Extraterrestrial Physics, Garching, Germany

Background:
Plasma medicine is a relatively new scientific field with great therapeutic potential. A recent prospective randomized controlled trial has shown that cold argon plasma has beneficial effects on wound healing by decreasing the bacterial load. To identify additional therapeutic possibilities and to look into new potential applications, we investigated the treatment of pruritic diseases, which often represent a therapeutic challenge. Pruritus is known to be the most frequent dermatological symptom which considerably impairs the quality of life of patients particularly as chronic condition.

Objectives:
To assess the efficacy and safety of cold atmospheric argon plasma treatment as an add-on therapy for patients with various types of pruritic diseases.

Patients and methods:
In this prospective randomized controlled phase II study, we treated 46 patients with pruritic diseases of different etiology, for example, atopic eczema, prurigo, drug eruption, etc., with cold atmospheric argon plasma for 2 min daily in addition to standard treatment (topical and systemic drugs, UV phototherapy). All patients were used as their own control, and the control skin areas were treated with argon gas. The treatment device was the MicroPlaSter® developed by the Max Planck Institute for Extraterrestrial Physics (Fig. 1).

The outcome measure was a reduction in itching measured by means of a visual analogue score (VAS) from 0 to 10 on antipruritic long- and short-term effects. Further analyses were made to detect differences between the treatment with cold atmospheric argon plasma and argon gas only, neither with regard to antipruritic long-term effects (mean VAS difference of 1.97 (SD 1.33) for plasma treated areas; 1.74 (SD 2.37) for argon gas treated areas; p=0.224, 95% CI: [-0.15; 0.60]) nor to short-term effects (mean VAS difference of 1.92 (SD 1.33) for plasma treated areas and 1.97 (SD 1.29); p=0.544, 95% CI: [-0.21; 0.11]) for argon gas (Fig. 3). In both groups, patients experienced a significant reduction of pruritus at the end of therapy compared to baseline (mean difference of 1.97 (p<0.0001) for plasma and 1.74 (p<0.0001) for placebo). The analyses for the between-subject factors gender (female vs. male), duration (acute ≤ 6 weeks vs. chronic > 6 weeks) and the risk factor stress (stress vs. not stressed) did not differ statistically.

No relevant side effects occurred, and plasma treatment was well-tolerated.

Results:
An average of 4.74 cold argon plasma and argon gas (as control) treatments were administered per randomized area (ranging from 1 to 14, total treatments n = 218).

VAS scores at baseline were comparable in both groups: plasma 4.57 (SD 2.38) and argon gas 4.34 (SD 2.35). We found no significant differences in VAS reduction between the treatment with cold atmospheric argon plasma and argon gas only, neither with regard to antipruritic long-term effects (mean VAS difference of 1.97 (SD 1.33) for plasma treated areas; 1.74 (SD 2.37) for argon gas treated areas; p=0.224, 95% CI: [-0.15; 0.60]) nor to short-term effects (mean VAS difference of 1.92 (SD 1.33) for plasma treated areas and 1.97 (SD 1.29); p=0.544, 95% CI: [-0.21; 0.11]) for argon gas (Fig. 3).

No significant differences in VAS reduction were found between the treatment with cold atmospheric argon plasma and argon gas only.

Conclusion:
✓ Cold atmospheric plasma treatment did not result in higher pruritus reduction than treatment with argon gas only, although each treatment led to a significant reduction of pruritus.
✓ Both treatment options had similar tolerability and proved to be safe.

Acknowledgement:
We thank ADTEC Plasma Technology Co. Ltd. Hiroshima for the allocation of the MicroPlaSter®.

Contact:
Julia Heinlin, Department of Dermatology, University Hospital Regensburg, Germany e-mail: julia.heinlin@klinik.uni-regensburg.de